Oil, Water, and Kicks - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Oil, Water, and Kicks


Pharmaceutical Technology

HomoGENIUS not


Control
A particular dermatological product was packaged in a metal tube, which is filled from the bottom. The tube is then closed, crimped, and the lot number is debossed on the crimp. There were several complaints about the product, including "bleeding" of the ointment. Apparently, the ointment was separating into an oil phase and a solid phase, and drops of oil were seeping out of the crimped tube bottom. In fact, an inspection of retained samples showed quite a few samples had discolored cartons because of the seepage.

Our GMP agent-in-place brought up these issues, along with a proposed solution: reformulate. The required resources were not allocated, and production continued.

When the product had to be transferred to another manufacturing facility, the FDA reviewing division checked on the homogeneity of production at the new site (evidently based on complaints that they had received for this product). Based on the FDA's request, a homogeneity test was added for the first three production batches, without a specification. Because the homogeneity test was just an assay repeated 10 times, the assay result was calculated as the average of the homogeneity. And because there were no set specifications for homogeneity, it always passed, even if one or more of the individual assays were out of specification.

Well, FDA got a hold of these data, ultimately issued a Warning Letter, and requested the recall of one product lot. "Of course," sighs our long-suffering GMP agent, "only after all of this happened were the resources allocated for the reformulation, and a real content uniformity specification was set for the homogeneity test."

Hot water problem gets the cold shoulder

At a particular manufacturing site, the cold water-for-injection [WFI] system was designed to provide up to 500 gallons per hour. "As production volumes went up, the usage requirements went up as well," explains our GMP Agent-in-Place. "The primary control for the system was to maintain pressure. The other controls were secondary. The system would turn on the cooling if the temperature rose, but not stop usage. To maintain the pressure, it would feed in hot WFI as the pressure source."

At times of peak usage, the heat exchanger used to cool the hot WFI into cold WFI was overtaxed, and the hot WFI would then flow directly into the cold WFI loop. The temperature charts showed this temperature fluctuation at times of peak usage.

"I saw this but couldn't get the attention of manufacturing or engineering," moaned our GMP Agent. "Nothing was done until an FDA inspector found it. The end result, due to this and other more serious problems, was a consent decree of permanent injunction for the site."

Just for kicks

"The vice-president of corporate regulatory came to visit our manufacturing site and the manager of incoming product release and I were hosting him," recalls our GMP Agent-in-Place. "The VP was concerned about the fit of stoppers into vials, and wanted us to control chart a lot of data."

But this site made tens of millions of vials per year. The added workload for the exact measurement using micrometers plus this control charting work would require about five more people, which we couldn't afford. "I tried to argue with the VP along these lines (bang for the buck)," says our practical GMP agent, "but the manager kicked me under the table, and we both agreed with him. The VP left happy." Of course the manager couldn't do the testing without the staff and didn't. "After that meeting, whenever my manager agrees to do something, I always ask with a grin, 'Are you really going to do this?'"

Pharmaceutical Technology's monthly "Agent-in-Place" column distills true-life cautionary tales from the secret files of Control, a senior compliance officer. If you have a story of clueless operators, oblivious management, inopportune lapses of judgment, or Murphy's Law in action, please send it to Control at
. We won't use any names, but if we do use your tale of disaster, courage, or just plain weirdness, Control will send you a coveted Pharmaceutical Technology t-shirt.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here